Medical Device Innovation and Reimbursement: MDMA 2016 Conference Notes

Read notes from MDMA Reimbursement Conference presentations 2016

Perspectives on Medical Reimbursement By JR Associates Through the years, our consultants have become popular as featured speakers at a variety of prestigious medical technology forums. But the highlight of our annual events calendar is always the MDMA Coverage, Reimbursement & Health Policy Conference. It is deeply rewarding to connect directly with medical device professionals and discuss critical…

Read More »

How Can Medical Innovators Build a Case for Reimbursement?

Perspectives on Medical Reimbursement By JR Associates Coverage. Coding. Payment. These three factors deeply influence reimbursement for every new medical technology product. But there are no “cookie cutter” solutions. Because the reimbursement landscape is so complex and time consuming, it’s smart to start preparing for reimbursement as early as possible in the business planning and product development process. But…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How medical technology innovators can leverage reimbursement strategy across markets

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

ICD-10 Impact on Cardiac Rhythm Management Procedure Coding

ICD 10 Impact on Cardiac Rhythm Management

Perspectives on Medical Reimbursement Issues By JR Associates Whitepaper: Impact of ICD-10 on Coding and Reimbursement for Cardiac Rhythm Management Procedures Authors: • Beth Bontemps, MSN, RN, NP, CCS Senior Consultant, JR Associates, Inc. • Rayellen Gilles, Customer Experience, Wolters Kluwer Law & Business Summary: By October 1, 2013, all U.S. healthcare providers are required to…

Read More »

Amyvid & Alzheimers Lesson: FDA Approval Is Not A Coverage Guarantee

Perspectives on Medical Reimbursement By JR Associates The path to advancements in disease detection and treatment is notoriously complex, circuitous and costly. However, even after FDA approval, there are no guarantees of reimbursement through CMS coverage. This is an essential lesson in the case of Eli Lilly’s Amyvid PET scan imaging agent, which is used…

Read More »

JR Associates Adds VP Global Health Policy

New Consultant Position Solidifies Reimbursement Consulting Firm’s Commitment to International Clients Los Angeles, CA — June 30, 2011 — JR Associates, reimbursement advisors to some of the world’s most innovative medical device companies, today announced that Jo Ellen Slurzberg has joined the firm as Vice President, Global Health Policy. With decades of extraordinary reimbursement accomplishments…

Read More »